A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors

NCT07169734 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Squamous Cell Carcinoma
Squamous Non-small-cell Lung Cancer
Colorectal Cancer
Intrahepatic Cholangiocarcinoma
Urothelial Carcinoma

Interventions

DRUG: ALE.P03
DRUG: ALE.P03
DRUG: ALE.P03

Sponsor

Alentis Therapeutics AG